Platinib scope of application and role introduction

Pralsetinib , trade name is Pujihua, is an innovative anti-cancer drug that specifically targets cells expressing RET gene mutations and shows significant inhibitory effects. As an inhibitor of the receptor tyrosine kinase RET, platinib is the first selective RET inhibitor approved for marketing in China. It effectively inhibits the phosphorylation of RET and its downstream molecules, thereby inhibiting the proliferation of cancer cells carrying RET fusion genes, providing a new approach to cancer treatment.

Platinib has a wide range of applications and is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for transfection rearrangement (RET) gene fusion. In addition, it is also indicated for adults and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic treatment. Platinib has also shown promising results in adults and children aged 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine.

In clinical studies, platinib has shown impressive efficacy. For example, in the ARROW study, for patients with RET fusion-positive metastatic NSCLC who had previously received platinum-based chemotherapy, the overall response rate (ORR) and duration of response (DOR) after platinib treatment reached satisfactory levels. These data provide strong support for the use of platinib in anticancer treatment.

In general, platinib, as a new anti-cancer drug, provides a new treatment option for cancer patients with RET gene mutations through its unique mechanism. Its wide scope of application and significant therapeutic effect make platinib an important position in the field of anti-cancer. With the deepening of research and the expansion of clinical application, platinib is expected to bring hope and vitality to more cancer patients.